TRIM29 expression and its survival predictor value in colorectal cancer with different primary tumor location.

Abstract

e15528 Background: It is clear that, in colorectal cancer (CRC), patients with different primary tumor location have variant prognosis and distinct clinicopathological features.So, it is very necessary to find specific tumor markers for different tumor sites.Our previous study have found TRIM29 is higher expressed in right colon cancer(RCC) than left colon cancer(LCC) patients in a small sample size reviewed study.So we speculated TRIM29 have different effect on the patients with different tumor side.But in our previous study, we didn’t investigate the TRIM29 expression in rectal cancer patients(RECC) and observed the effect of TRIM29 on the survival by different tumor side patients.So we decide to explore whether TRIM29 plays a different role in patients with three different tumor sites in a larger sample size study. Methods: 227 CRC cases were included in our retrospectively study,the patients were divided into LCC, RCC and RECC three groups. We first tested TRIM29 mRNA and protein expression level in LCC, RCC and RECC respectively to confirm whether TRIM29 expressed differently in patients with different tumor location. Then we explore the relationship between TRIM29 and clinicopathologic features in the patients with three tumor sites respectively.At last, we explore whether TRIM29 has different effect on the survival of the patients with three different tumor location. Results: TRIM29 mRNA and protein expression was significantly higher in RCC than in LCC and RECC ( P< 0.0001, P< 0.001).High TRIM29 expression was only associated with intestinal obstruction before surgery in LCC patients( P = 0.006) and it was associated with higher frequency of stage TNM IIĨIV and younger patients in RECC( P = 0.015 and 0.000), whereas it was associated with higher frequency of male, elder, stage IIĨIV patients, N+ and intestinal obstruction patients in RCC( P = 0.000,0.000,0.000,0.000 and 0.010).Only in the RCC group, patients with high TRIM29 expression both had a significant difference in the risk of recurrence/metastasis and death compared to patients with low TRIM29 expression( P = 0.020,0.000). Conclusions: TRIM29 plays different role in the patients with different tumor sites.TRIM29 has a greater correlation with clinicopathological features and greater effect on the prognosis in right colon cancer.TRIM29 may serve as a new biomarker and a novel therapeutic target in RCC patients.